Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAVASAB: Daptomycin vs Vancomycin for MRSA Bacteremia
NCT01515020Phase 3Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2012
- Primary completion
- Jun 2013
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daptomycin in Staphylococcus aureus bacteremia (SAB) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Rates of sterilization of blood cultures after 72 hours of therapy. Started May 2012; status: terminated.
02
Drugs
daptomycin
03
Conditions
Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT01515020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01515020.